Highlighted by Amylyx, the ALS Space is Gaining Momentum

While all eyes this week have been on Amylyx, whose amyotrophic lateral sclerosis (ALS) drug candidate AMX0035 won the recommendation of an FDA advisory committee Wednesday, there are several other approaches on the horizon in a space that is picking up momentum.

With unstoppable progression, ALS has proven to be difficult to treat - arresting the development of its relentless course is the holy grail.